Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), especially the Delta and Omicron variants, have been reported to show significant resistance to approved neutralizing monoclonal antibodies (mAbs) and vaccines. We previously identified a mAb named 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yao, Yue, Shuai, Yang, Yang, Yang, Sen, Pan, Zhiwei, Yang, Xiaofan, Gao, Leiqiong, Zhou, Jing, Li, Zhirong, Hu, Li, Tang, Jianfang, Wu, Qing, Lei, Shun, Tian, Qin, Wang, Yifei, Hao, Yaxing, Xu, Lifan, Huang, Qizhao, Zhu, Bo, Chen, Yaokai, Chen, Xiangyu, Ye, Lilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214129/
https://www.ncbi.nlm.nih.gov/pubmed/35666466
http://dx.doi.org/10.1093/cid/ciac448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214129/
https://www.ncbi.nlm.nih.gov/pubmed/35666466
http://dx.doi.org/10.1093/cid/ciac448

Ejemplares similares